Skip to content
News Coverage

Despite research boom, few immunotherapy studies targeting pancreatic cancer

Dive Brief:

  • Among the more than 2,600 clinical trials testing the most successful type of cancer immunotherapy, only 89, or about 3%, target pancreatic cancer, according to a new analysis unveiled Sunday by the nonprofit Cancer Research Institute.
  • Pancreatic cancer remains one of the toughest tumor types to treat, and currently ranks as the third leading cause of cancer-related death in the U.S. — making the relative dearth of immunotherapy trials studying new treatment approaches notable.
  • Still, some progress is being made. A study led by the Parker Institute for Cancer Immunotherapy and funded by CRI, results of which were also disclosed Sunday, showed combining immunotherapy together with chemotherapy could hold potential in treating metastatic pancreatic ductal adenocarcinoma, the most common subtype of the cancer.

Read More

Get Email Updates